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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYIn this study, human embryonic stem cell-derived hepatocytes (hESC-Heps) were investigated for their ability to support hepatitis C virus
(HCV) infection and replication. hESC-Heps were capable of supporting the full viral life cycle, including the release of infectious virions.
Although supportive, hESC-Hep viral infection levels were not as great as those observed in Huh7 cells.We reasoned that innate immune
responses in hESC-Heps may lead to the low level of infection and replication. Upon further investigation, we identified a strong type III
interferon response in hESC-Heps that was triggered by HCV. Interestingly, specific inhibition of the JAK/STAT signaling pathway led to
an increase in HCV infection and replication in hESC-Heps. Of note, the interferon response was not evident in Huh7 cells. In summary,
we have established a robust cell-based system that allows the in-depth study of virus-host interactions in vitro.INTRODUCTION
Hepatitis C virus (HCV) infects an estimated 2%–3% of the
world population and is a major cause of liver disease and
cancer. It is estimated that more than 350,000 people die
of the HCV-related liver disease each year (Te and Jensen,
2010; Yang and Roberts, 2010). Although the efficacy of
current treatments has improved considerably, the high
genetic variation of the virus still poses significant issues.
Therefore, to develop new targets for effective therapy, it
is necessary to gain greater understanding of the processes
that control viral infection, replication, and ultimately
pathogenesis.
The organ primarily affected by HCV is the liver. HCV
entry into target cells occurs via receptor-mediated endocy-
tosis and fusionwith intracellularmembranes. This process
requires multiple attachment and entry factors. Among
those, CD81, scavenger receptor class B type 1 (SR-B1),
claudin 1, and occludin play a critical role (Evans et al.,
2007; Pileri et al., 1998; Ploss et al., 2009; Scarselli et al.,
2002). Postviral infection, the host innate immune system
is the first line of defense. Human hepatocytes mount their
initial immune response, producing interferon (IFN)
(Horner and Gale, 2013; Kotenko et al., 2003; Takeuchi
and Akira, 2009). IFNs are released from the infected cells
and serve to reduce viral replication and spread (Dicken-
sheets et al., 2013).
In order to limit the persistence, and therefore the
pathology associated with HCV, it is imperative that we
develop a better understanding of virus-host interactions.
Cell-based models that support HCV propagation have204 Stem Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The Authorsprovided the field with enabling technology. Although
enabling, current models possess significant drawbacks,
including diminished innate immunity (Foy et al., 2005).
Therefore, if we are to gain a better understanding of
HCV life cycle and associated pathogenesis, biologically
relevant model systems, whichmore closely mimic human
physiology, must be developed. For this reason, primary
human hepatocytes (PHHs) have been employed. How-
ever, their scarcity, inconsistency, and rapid dedifferentia-
tion in culture impede their widespread deployment.
The delivery of human hepatocytes, from a renewable
source, is therefore an attractive strategy to bypass the
issues associated with primary material (Sun et al., 2013;
Hay, 2013). Of note, several reports have demonstrated
the potential of pluripotent stem cells to deliver functional
hepatocytes (Cai et al., 2007, Duan et al., 2007, Hay et al.,
2008, 2011; Medine et al., 2013; Si-Tayeb et al., 2010;
Sullivan et al., 2010; Szkolnicka et al., 2014; Zhou et al.,
2012; Lucendo-Villarin et al., 2012). Most recently, stem
cell-derived hepatocytes have been used to support HCV
infection (Roelandt et al., 2012; Schwartz et al., 2012; Wu
et al., 2012); however, the host innate immune response
has not yet been studied in detail.
To study this in detail, we employed a robust and serum-
free hepatocyte differentiation procedure (Szkolnicka
et al., 2014). Human embryonic stem cells were efficiently
differentiated toward the hepatocyte lineage. Importantly,
those cells expressed critical viral receptors, supported the
full life cycle of HCV and exhibited a ‘‘tunable’’ type III
interferon response, which was not intact in Huh7s. There-
fore, human embryonic stem cell-derived hepatocytes
Figure 1. Hepatocyte Differentiation from Human Embryonic Stem Cells
(A) Morphologic change of hESCs to hESC-Heps during cellular differentiation. Scale bar, 100 mm.
(B) At day 19 hESC-Heps were fixed and immunostained for the hepatic markers Albumin/HNF4a/E-cadherin and hESC marker OCT4. Scale
bar, 100 mm.
(C) Following 16 and 19 days of differentiation, hESC-Heps exhibited increasing CYP3A4 and CYP1A2 metabolic activity, which were
measured using p450-Glo systems (Promega). Relative luminescence unit (RLU) values were normalized to protein (mg) and medium
volume (ml), and shown as the mean ± SD. Error bars represent the SD of the mean. n = 6, biological replicates.
See also Figure S1 and Table S2.
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Inducing Innate Immunity in hESC-Hepatocytes(hESC-Heps) represent an important, defined, and renew-
able model system with which to study HCV.RESULTS
Robust Hepatocyte Differentiation from Pluripotent
Stem Cells
hESCs were cultured and differentiated using previously
described conditions (Szkolnicka et al., 2014). In
line with morphological changes (Figure 1A), we observed
changes in gene expression confirming hepatocyte
commitment. OCT4 expression was not detected in
stem cell-derived hepatocytes (0%). In contrast, albumin,
HNF4a and E-cadherin were expressed in 87% (±5%),Ste90% (±4%), and 92% (±2%) of cells, respectively (Fig-
ure 1B). Furthermore, stem cell-derived hepatocytes ex-
hibited liver specific function. This peaked at day 19 with
the greatest cytochrome P450 3A (CYP3A) and cytochrome
P450 1A2 (CYP1A2) activities detected (Figure 1C). These
data demonstrate the robust delivery of hESC-Heps, which
were suitable in character for further modeling studies.
hESC-Heps Express the Essential HCV Entry Factors
hESCs and hESC-Heps were fixed and immunostained for
the major HCV host cell entry factors; CD81, SR-B1, clau-
din-1, and occludin (Evans et al., 2007; Pileri et al., 1998;
Ploss et al., 2009; Scarselli et al., 2002). Claudin-1 expres-
sion was not detected in hESCs, whereas it was abundant
in hESC-Heps (90% ± 5%). The other viral entry factorsm Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The Authors 205
Figure 2. hESC-Heps Express the Essen-
tial HCV Entry Factors
(A) Immunostaining of occludin, CD81, SR-
BI, and claudin-1 in hESCs and hESC-Heps.
Scale bar, 100 mm.
(B) Western blotting for HCV entry factors
(occludin, CD81, SR-BI, and claudin-1),
stem cell (OCT4), and cell differentiation
(AFP) markers in Huh7, hESCs, and hESC-
Heps, respectively.
(C) The expression level of HCV entry factors
in hESC-Heps and Huh7, relative to hESC,
was determined by qPCR.
Error bars represent the SD of the mean.
n = 3, biological replicates. See also Tables
S1 and S2.
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increased in hESC-Heps. Expression of occludin, CD81,
SR-B1, was estimated at 92% (±4%), 90% (±5%), and
84% (±4%), respectively (Figure 2A). These results were
confirmed by western blotting and quantitative PCR
(qPCR) (Figures 2B and 2C), suggesting that hESC-Heps
would support HCV entry.
hESC-Heps Support HCV Infection and Infectious
Virion Production
To test our hypothesis, HCV strain JFH-1 (Wakita et al.,
2005) was selected to infect hESC-Heps. This strain repli-
cates efficiently in Huh7 cells. At 96 hr postinfection,
HCV nonstructural protein NS5A and core protein expres-
sion were detected in hESC-Heps by immunostaining
demonstrating viral entry (Figure 3A). Infected foci were
visualized by NS5A staining, and the total focus number
per well of 12-well plate (3.8 cm2) were calculated. The206 Stem Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The Authorssize of infected foci was measured as average number of
cells per focus (Calland et al., 2012). The average number
of infected foci per well and the size of the infected foci
were 242.5 ± 82.3 and 4.2 ± 1.8, respectively. To test for
viral entry, we also examined HCV RNA levels in the pres-
ence or absence of a HCV polymerase inhibitor (20CMA).
The HCV RNA levels relative to HCV with 20CMA group
were measured by qPCR. In line with previous studies,
20CMA inhibited HCV replication in hESC-Heps indicating
assay specificity (Figure 3B). In addition to infection and
viral genome replication, we were interested in studying
virus assembly and secretion. To assess this, the presence
and infectious titer of the virus progeny from hESC-Heps
were calculated by performing a focus-forming unit
(FFU) assay in Huh7 cells (Figure 3C and Figure S2 avail-
able online). hESC-Heps were capable of supporting HCV
life cycle, including the release of new infectious virions.
However, we noted that the level of infection and
Figure 3. HCV Infection of hESC-Heps
and Huh7
(A) Day 19 hESC-Heps were exposed to JFH-
1-based HCVcc. Three days postinfection,
cells were double stained for HCV core
(red) and NS5A (green). Nuclei were coun-
terstained with DAPI (blue). Scale bar,
100 mm.
(B) hESC-Heps were either mock infected or
infected with HCV in the presence or
absence of 20CMA. HCV RNA levels, relative
to HCV with 20CMA group, were detected
by qPCR.
(C) At 72 hr postinfection, the infectious
virus yield in the medium of infected Huh7
or hESC-Heps was determined on naive
Huh7 cells by focus-forming assay, and the
values presented as focus-forming units
(FFU) per ml (log10).
(D) Comparison of HCV RNA levels in
infected cells by qPCR. Fold change relative
to that of 24 hr postinfection in hESC-Heps
(black line) or Huh7 (red line) cells was
calculated.
(E) Antiviral activity of conditioned
medium from hESC-Heps infected by HCV.
Huh7-J20 reporter cells preinfected with
HCV for 3 hr were incubated for 48 hr with
the supernatants from hESC-Heps collected
at 0, 4, 24, or 48 hr postinfection with
HCV. The effect of hESC-Hep supernatants
on virus infection in Huh7-J20 cells was determined by measuring SEAP activity in the medium, which correlates directly with
virus replication. **p < 0.01, ***p < 0.001 compared with the group of 0 hr postinfection.
Error bars represent the SD of the mean. n = 3, biological replicates. See also Figure S2 and Tables S1 and S2.
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cells. In support of this, we found that HCV replication
plateaued in hESC-Heps by 48 hr, but this was not
observed in Huh7 cells, even at the 72 hr time point (Fig-
ure 3D). To test if the medium of HCV-infected hESC-Heps
carried antiviral activity, we incubated the reporter cell
line Huh7-J20 that had been preinfected with HCVcc,
with hESC-Hep supernatant collected at various times
postinfection. Of note, there was a significant inhibition
of HCV replication in Huh7-J20 cells when they were incu-
bated with the medium collected from hESC-Heps (Fig-
ure 3E). These data strongly suggest the presence of key
factor(s) in the infected hESC-Heps supernatants that
likely accounted for the inhibition of viral replication
observed in the Huh7-J20 cells.
HCV Infection of hESC-Heps Activates a Type III IFN
Response
Given the important role that the IFN response plays in
defense against microbial and viral infection, we opted
to study gene expression of key immune mediators.StehESC-Heps were infected with HCVcc for 4 hr, before
replacing with fresh cell medium. Seventy-two hours
postinfection, total RNA was prepared and profiled using
an IFN-stimulated gene (ISG) PCR array. In response to
HCV infection, hESC-Hep gene expression was represen-
tative of a type III IFN response (Table 1). These findings
were corroborated by qPCR (Figure S3) and strongly
implicated interleukin (IL)-29, the dominant type III IFN
produced by primary human and primate hepatocytes
in response to hepatitis C virus infection (Park et al.,
2012).
To confirm that IL-29 was eliciting a strong activation of
ISGs in our model, we incubated hESC-Heps with recombi-
nant IL-29 (Table 1). Recombinant IL-29 activated the JAK/
STAT pathway in hESC-Heps (Figure 4A), leading to the
phosphorylation of STAT1 and induction of ISG expression
(IFIT1, MX1, OAS1, ISG15, CXCL10, IRF9, IRF7, IRF1, and
IRF2) in line with the literature (Figures 4A and 4B; Table 1).
In contrast to hESC-Heps, very little or no induction of
RIG-I, ISG15, CXCL10, CXCL11, and IFIT1 gene expression
was observed in Huh7 cells (Figure 4B).m Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The Authors 207
Table 1. Increase of IFNs and ISG Expression in Stem Cell-Derived Hepatocytes after Treatment with IL-29 or HCV
Gene Symbol RefSeq
Fold Increase
Gene DescriptionIL-29 Treatment HCV Treatment
IFIT1 NM_001548 2,488.73 4.64 IFN-induced protein with tetratricopeptide repeats 1
IFI27 NM_005532 927.55 5.91 alpha-inducible protein 27
IFI44 NM_006417 389.86 6.64 IFN-induced protein 44
IFI44L NM_006820 216.25 2.54 IFN-induced protein 44-like
IFIT2 NM_001547 152.75 3.41 IFN-induced protein with tetratricopeptide repeats 2
IFI6 NM_002038 111.52 5.12 IFN, alpha-inducible protein 6
CXCL10 NM_001565 110.63 4.32 chemokine (C-X-C motif) ligand 10
OAS1 NM_002534 88.16 5.73 20-50-oligoadenylate synthetase 1, 40/46 kDa
ISG15 NM_005101 52.36 4.35 ISG15 ubiquitin-like modifier
IFIH1 NM_022168 51.89 4.19 IFN induced with helicase C domain 1
IFITM1 NM_003641 20.27 6.29 IFN-induced transmembrane protein 1 (9–27)
IRF7 NM_001572 18.56 12.51 IFN regulatory factor 7
IFNA8 NM_002170 16.90 6.49 IFN, alpha 8
IFI35 NM_005533 11.27 5.65 IFN-induced protein 35
MX1 NM_002462 11.26 4.66 myxovirus (influenza virus) resistance 1, IFN-inducible protein p78 (mouse)
IL-29 NM_172140 10.99 7.10 IL-29 (IFN, lambda 1)
See also Table S3.
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in hESC-Heps
To further establish the role of IFN response in our
cell-based model, hESC-Heps were transfected with pol-
yinosinic/polycytidylic acid (polyI:C) to mimic intracel-
lular viral RNA. Twenty-four hours posttransfection, we
observed upregulation of both type I (IFN-a and IFN-b)
and type III IFNs (IL-28 and IL-29) by PCR or ELISA (Fig-
ures 5A and 5B). Of note, IRF9, a JAK/STAT pathway
enhancer (Samuel, 2001), and RIG-1, a detector of extra-
neous double-stranded RNAs (dsRNAs) responsible for
IFNb production (Kato et al., 2006), were also upregulated.
Additionally, inflammatory chemokines (CXCL10 and
CXCL11) and antiviral ISGs (IFIT1, MX1, and ISG15)
were also strongly stimulated by dsRNA (Figure 5A). To
study the effect of host factors generated in hESC-Heps
after polyI:C treatment on viral replication, supernatant
collected from transfected hESC-Heps were transferred
to the infected Huh7-J20 reporter cells. In support of our
previous experiments (Figure 3E), the supernatants of
polyI:C-treated hESC-Heps possessed antiviral agents,
including IL-29 (Figure 5B), strongly inhibiting virus repli-
cation (Figure 5C).208 Stem Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The AuthorsInhibition of JAK/STAT Pathway Promotes HCV
Replication in hESC-Heps
To improve viral infection and replication in hESC-Heps,
we hypothesized that downregulation of the IFN response
was necessary. To test this hypothesis, we pretreated
hESC-Heps with JAK/STAT inhibitor (JAK Inhibitor I;
10 mM) for 1 hr prior to infection. HCV replication was
significantly increased in JAK/STAT-inhibitor-treated
hESC-Heps (Figure 6). We observed that the infected foci
were larger in hESC-Heps treated with a JAK/STAT inhib-
itor (Figure 6A). In the hESC-Heps without inhibitor pre-
treatment, the total number of infected foci was 284.3 ±
94.5 per well of 12-well plate, and the average size of
infected foci was 3.8 ± 3.1. In contrast, hESC-Heps pre-
treated with the inhibitor, the number of infected foci
was 241.2 ± 77.5, and the average size of infected foci
was 14.3 ± 5.8. In line with this observation, HCV RNA
level in JAK/STAT-inhibitor-treated hESC-Heps was signif-
icantly increased (Figure 6B). Moreover, we also detected
increases (>2-fold) in ISG expression (IFI27, IFI44,
IFI44L, CXCL10, ISG15, IFIH1, IFITM1, IFNA8) in cells
treated with the JAK/STAT inhibitor and following infec-
tion (Table S4).
Figure 4. Induction of Innate Immune Response in hESC-Heps by IL-29
(A) hESC-Heps were stimulated with different concentrations of IL-29. Proteins were extracted, and phosphorylated STAT1 and loading
control, b-actin, were detected by western blotting.
(B) hESC-Heps or Huh7 cells were treated with 100 ng/ml IL-29 for the different times as indicated. Total RNA was isolated and reverse
transcribed, and then qPCR was performed for the named genes.
Error bars represent the SD of the mean. n = 3, biological replicates. See also Tables S1 and S2.
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facilitated HCV replication, we collected the supernatants
from JAK/STAT-inhibitor-treated hESC-Heps, Huh7, or con-
trol cells and examined their effect on HCV replication in
the Huh7-J20 reporter cell line (Figure 6C). Strikingly,
only supernatants collected from JAK/STAT-inhibitor-
treated hESC-Heps (Figure 6D), not Huh7s (Figure 6E),
significantly increased HCV replication.DISCUSSION
Pluripotent stem cells are scalable and retain the ability to
formevery cell type in thehumanbody. Theability toderiveStehuman soma in limitless amounts offers great possibilities
for regenerativemedicine and cell-basedmodeling. In these
studies,weusedhESCs toderivehumanhepatocytes. hESCs
were differentiated using established procedures (Szkol-
nicka et al., 2014). Thederivative cellsdisplayed stablehepa-
tocyte function (Figure 1), expressed the main entry factors
for HCV (DaCosta et al., 2012; Evans et al., 2007) (Figure 2),
and supported full virus life cycle, including the release of
infectious progeny (Figures 3, 4, 5, and 6).
Although ourmodel supported viral life cycle, there were
key elements of the system that required more detailed
attention. Despite robust infection, hESC-Heps and pri-
mary hepatocytes produce less infectious virions than
Huh7 line (Liang et al., 2009; Ploss et al., 2010; Podevinm Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The Authors 209
Figure 5. ISG Response of hESC-Heps
to dsRNA
(A) IFN and ISG mRNA were determined by
qPCR in polyI:C relative to mock-transfected
hESC-Heps.
(B) IL29 secretion in polyI:C-treated hESC-
Heps was measured by ELISA.
(C) Antiviral activity of conditioned
medium (CM) from polyI:C-treated hESC-
Heps cells. Huh7-J20 reporter cells were
first infected with HCVcc for 3 hr and then
they were incubated with CM from hESC-
Heps treated with 0, 1, 5, or 10 mg/ml
polyI:C. At 72 hr postincubation SEAP
activity in the medium, which correlates
directly with viral RNA replication, was
measured. The SEAP levels are presented as
relative light units (RLUs). **p < 0.01
compared with the group treated with
0 mg/ml polyI:C.
Error bars represent the SD of the mean.
n = 3, biological replicates. See also Tables
S1 and S2.
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We hypothesized the lesser infection of hESC-Heps
may be due to a robust induction of cellular immunity.
Indeed, after HCV infection, hESC-Heps demonstrated
strong induction of IL-29, followed by IFN-stimulated
gene (ISG) expression. This was lesser in Huh7 cells and
is likely attributable to defects in retinoic acid-inducible
gene 1 (RIG-1) pathway (Sumpter et al., 2005). These
observations were tested extensively in vitro, and further
supported by studies in which extraneous RNA was intro-
duced to the cells to stimulate the IFN response (Park
et al., 2012).
Following the demonstration that the IFN response was
intact, we sought to alter the dynamics of this system to
see if we could improve viral infection and replication.
In these studies, we chose one of the major signaling path-
ways effecting the IFN response. Through the use of a JAK/
STAT pathway inhibitor, it was possible to attenuate the
hESC-Hep innate immune response. In line with reduced
JAK/STAT activity, hESC-Heps displayed enhanced HCV
replication, which was most likely attributable to cell-to-
cell transmission of virus. Notably, innate immunity was210 Stem Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The Authorsnot intact in the Huh7 line, highlighting the need to
develop new models of HCV biology, which more accu-
rately reflect virus-host interactions.
In conclusion, although infection in hESC-Heps has
been established, it is relatively low (Roelandt et al.,
2012; Wu et al., 2012). Prior to these studies, the reason
for this had proved elusive. We provide evidence that by
modulating the JAK/STAT pathway and the downstream
IFN response, hESC-Hep infection and subsequent repli-
cation is ‘‘tunable.’’ This, in combination with the scal-
able nature of our system and the defined genetics, pro-
vides the field with an important model and platform
technology.EXPERIMENTAL PROCEDURES
Reagents
RPMI, 503 B27 Supplement, Knockout DMEM (KO-DMEM),
Knockout Serum Replacement Medium (KO-SR), GlutaMAX,
Penicillin/Streptomycin (P/S), and HepatoZYME-SFM (HZM)
were purchased from Life Technologies. Recombinant Mouse
Wnt3a, Human Activin A (AA), HumanHepatocyte Growth Factor
Figure 6. JAK Inhibitor I Improves HCV
Infectivity in hESC-Heps
(A) hESC-Heps pretreated (bottom panel) or
not (top panel) with 10 mM JAK inhibitor I
were infected with HCVcc. At 3 days post-
infection, cells were immunostained for
viral NS5A antigen (green) and counter-
stained with DAPI (blue). Scale bar, 200 mm.
(B) hESC-Heps were pretreated with 0, 1, 5,
or 10 mM JAK inhibitor I before infection.
HCV RNA levels in infected hESC-Heps were
measured by qPCR. The results are presented
as fold change of HCV RNA level relative to
that of mock-treated cells.
(C) Generation of JAK-inhibitor-I-treated
conditioned medium (JTC). hESC-Heps or
Huh7 were pretreated for 1 hr with 0, 1, 5,
and 10 mM JAK inhibitor I, respectively,
before infection with HCVcc and the JTC at
72 hr postinfection was collected.
(D) JTC of hESC-Heps improved HCV infec-
tivity in human hepatoma cells. Huh7-J20
reporter cells were infected in advance by
HCV for 3 hr, washed with PBS, and then
incubated with JTC of hESC-Heps for 72 hr.
The virus infectivity levels were determined
by measuring SEAP activity in the medium.
(E) JTC of Huh7 has no effect on HCV
infectivity in human hepatoma cells.
Huh7-J20 reporter cells were infected in
advance by HCV for 3 hr, washed with PBS,
and then incubated with Huh7 JTC for 72 hr.
The virus infectivity was determined as
described in (D).
*p < 0.05, ***p < 0.001 compared with the
group treated with 0 mM JAK inhibitor I.
Error bars represent the SD of the mean.
n = 3, biological replicates.
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(Hannoun et al., 2010; Hay et al., 2011; Szkolnicka et al., 2013).
Hepatocyte Differentiation
H9 were maintained on MEF cells in MEF-CM (R&D Systems).
Before differentiation, H9 was passaged onto feeder-free Matrigel-
coated plates in mTeSR medium (STEMCELL Technologies). hESC
identity was assessed using a number of criteria including, the
absence of stage-specific embryonic antigen-1 (SSEA-1) expression
and presence of stage-specific embryonic antigen-4 (SSEA-4)
(Figure S1). A stepwise method for cellular differentiation was em-
ployed as described (Szkolnicka et al., 2014). Briefly, hESC (H9) dif-
ferentiation to endoderm was driven by incubating cells in RPMI/
B27 supplemented with 50 ng/mlWnt3a and 100 ng/ml Activin A
for 72 hr. Following which cells were maintained in 20% SR/
1% DMSO/KO-DMEM for a further 4–5 days to generate hepato-Steblastic populations. Hepatocytes were subsequently specified in
HepatoZYME-SFM (supplemented with 10 mM Hydro-cortisone,
10 ng/ml HGF, and 20 ng/ml OSM) for a further 10–15 days.
Immunofluorescence Staining for HCV Receptors
and Intracellular Antigens
Cells were fixed with ice-cold methanol for 10 min. After washing
with PBS-0.05% Tween 20 (PBST) and blocking in 0.5% BSA in PBS
for 1 hr, cells were incubated with primary antibodies overnight at
4C. Primary antibodies used were rabbit anti-human Oct4
(Abcam), mouse anti-human Albumin (Sigma-Aldrich), rabbit
anti-human HNF4a (Santa Cruz Biotechnology), mouse anti-
human E-cadherin (Abcam), mouse anti-human Occludin
(Invitrogen), mouse anti-human CD81 (Santa Cruz Biotech-
nology), mouse anti-human claudin-1 (Invitrogen), mouse anti-
human SR-BI (BD), mouse anti-NS5A (9E10, a kind gift fromm Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The Authors 211
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Rockefeller University, New York), rabbit anti-HCV core serum
(R308, a kind gift from John McLauchlan). Secondary antibodies
were Alexa Fluor 488 donkey anti-mouse (Molecular Probes), Alexa
Fluor 488 donkey anti-rabbit (Probe molecular), and Alexa Fluor
594 donkey anti-rabbit (Molecular Probes) conjugates. Details of
working dilution of each antibody are provided in Table S1. Cells
were counterstained with DAPI (Sigma-Aldrich), and the pictures
were captured by microscope of Zeiss Axio Observer.
CYP3A and CYP1A2 Assay
CYP3A and CYP1A2 assay were conducted as per the manufac-
turer’s instructions (Promega, CYP3A P450-GloTM Assay and
CYP1A2 P450-GloTM Assay). The relative light unit (RLU) of the
product was determined by the GloMax-96 Microplate Lumin-
ometer (Promega) and normalized to per milligram protein.
Western Blot Analysis
The XCell II Blot Module (Invitrogen) was employed according to
the manufacturer’s instructions. Total protein was extracted by
RIPA buffer (Pierce). The protein concentrations were measured
using the standard BCA assay (Pierce). Samples containing equal
amounts of total proteins were separated by Bis-Tris Gels (Life
Technologies) and electrophoretically transferred to PVDF
membranes (Bio-Rad). Blots were blocked with 5% BSA in TBST
(Tris-buffered saline containing 0.1% Tween 20) for 1 hr at room
temperature and then probed with primary antibody at 4C over-
night under constant rotation. The secondary antibody was incu-
bated for 1 hr at room temperature, and detected using SuperSignal
West Pico substrate (Thermo Scientific). Details of antibody sources
are provided in Table S1.
Preparation of Cell Culture Infectious HCV and
Infection
HumanhepatomaHuh7 cells were propagated inDulbecco’smodi-
fied Eagle’smedium (DMEM) supplementedwith 10%FBS (Gibco),
2 mM l-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 0.1 none essential amino acids. JFH-1-based HCVcc were pro-
duced in Huh7 cells as previously described (Wakita et al., 2005).
The HCVcc virus used in this study, JFH-1DSGCSL, is a JFH-1-derived
cell-culture adaptive mutant, the characterization of which will
be described elsewhere (A.G.N.A. and A.H.P., unpublished data).
HCVcc titers were determined by infection of Huh7 cells with
serial dilutions of virus, followed by indirect immunofluorescence
for HCV NS5A protein, and expressed as focus-forming units
(FFUs)/ml. These virus stocks at 107 FFU/ml were diluted ten times
in DMEMmedium and were used to inoculate hESC-Heps for 3 hr.
CultureswerewashedwithDMEMmediumandpropagated inHGF
andOSMcontainingmedium. To see the specificity ofHCVreplica-
tion, the HCVNS5B polymerase inhibitor 20CMA (generously sup-
plied byCraigGibbs [Gilead Sciences])was added to thehESC-Heps
3 hr postinfection at final concentration of 10 mM.
Determination of Virus Yield by Focus-Forming Assay
To test if infected hESC-Heps produced infectious virions, superna-
tants were harvested at 5 days postinoculation and serially diluted
to infect Huh7 cells. To assess viral NS5A antigen expression, the212 Stem Cell Reports j Vol. 3 j 204–214 j July 8, 2014 j ª2014 The Authorsinfected Huh7 cells were fixed in methanol, counterstained with
DAPI (Invitrogen), and immunostained with mouse anti-NS5A
(9E10) antibody followed by Donkey anti-mouse Alexa Fluor 488
(Invitrogen). NS5A foci formed in the plate were calculated and
the infectious virus yield presented as focus-forming unit (FFU)
per ml. Virus produced from infected Huh7 cells were used as a
control throughout.
Quantification of Virus Infectivity Using a Reporter
Cell Line
The Huh7-J20 reporter cell line has been described previously (Iro
et al., 2009). This cell line stably express eGFP fused in-frame to
secreted alkaline phosphatase (SEAP) via a recognition sequence
of the viral NS3/4A serine protease. The level of SEAP activity in
the culturemediumdirectly correlateswith the level of intracellular
viral RNA replication. Huh7-J20 cells seeded in a 96-well tissue cul-
ture plate were first infected with the virus for 3 hr after which the
inoculumwas replaced with freshmedium and the cells incubated
at37

Cfor3days.TheSEAPactivity in the infectedcellmediumwas
determined as described (Iro et al., 2009) using the Hidex Chame-
leon plate reader and expressed as relative light units (RLUs).
Quantitative PCR
Quantitative PCR was performed using the ABI 7500 instrument
and kit (ABI). Primers were designed separately to span at least
an intron. First-strand cDNA was used as a template. The relative
expression of the target genes to internal control (GAPDH) was
calculated by the comparative threshold cycle (DDCt) method.
Experiments were performed in triplicate.
PCR Array for IFN-Stimulated Gene Assay
The quality of RNA extracted by RNAeasy kit (QIAGEN) was
analyzed using a Nanodrop. One microgram of RNA was reverse
transcribed using the RT2 First Strand kit (QIAGEN). Real-time
PCR was performed to evaluate the expression of 84 genes using
RT2 profiler PCR array PAHS-064ZE (RT2 Profiler PCR Array Human
Interferons & Receptors, SABiosciences). Relative changes in gene
expression were calculated using the comparative threshold cycle
(DDCt) method. The GAPDH gene in array was used to normalize
to the RNA amount.
Polyinosinic/Polycytidylic Acid Transfection
of hESC-heps
hESC-Heps were transfected with 1, 5, or 10 mg polyI:C (tlrl-pic,
InvivoGen) lipofectamine 2000 (Invitrogen) as described (Park
et al., 2012). Supernatant and RNA were collected 24 hr after
infection and frozen at 20C and 70C, respectively.
IL-29 ELISA
IL-29 levels weremeasured using the human IL-29 sandwich ELISA
kit (eBioscience) according to manufacturer’s instructions.
Chemical Inhibitor Studies
hESC-Heps or Huh7 cells were exposed to 1, 5, 10 mM InSolution
JAK inhibitor 1 (Millipore) for 1 hr prior to infection with HCV.
Cells were infected with HCVcc at 10 FFU/ml for 3 hr and changed
Stem Cell Reports
Inducing Innate Immunity in hESC-Hepatocytesto fresh medium. Cultures were incubated for 5 days. During the
incubation, medium was renewed every 2 days. The supernatant
from infected cells were collected and stored at 4C prior to use
in the infectivity influence assay described below.
Infectivity Influence Assay
Huh7-J20 reporter cells were plated in a 24-well plate at 30%
confluence. Cells were first infected with HCVcc for 3 hr and
washed with DMEM. To test the influence of exogenous superna-
tant to the HCV replication, supernatant collected from either
polyI:C or JAK inhibitor I-treated cells were added to the infected
Huh7-J20 cells. The cells were incubated and themedium collected
after 3 days. The infectivity of HCV in collected medium was
measured by SEAP assay.
Statistical Analyses
Data collected from biological replicates are expressed as mean ±
SD. Differences between groups were examined for statistical
significance using Student’s t test, or one-way ANOVA followed
by Dunnett t tests; p values < 0.05 were regarded as significant.
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